Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial

BACKGROUND: Cardiomyopathy is a leading cause of death in patients with Duchenne muscular dystrophy and myocardial damage precedes decline in left ventricular systolic function. We tested the efficacy of eplerenone on top of background therapy in patients with Duchenne muscular dystrophy with early...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lancet Neurol
Autors principals: Raman, Subha V, Hor, Kan N, Mazur, Wojciech, Halnon, Nancy J, Kissel, John T, He, Xin, Tran, Tam, Smart, Suzanne, McCarthy, Beth, Taylor, Michael D, Jefferies, John L, Rafael-Fortney, Jill A, Lowe, Jeovanna, Roble, Sharon L, Cripe, Linda H
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4361281/
https://ncbi.nlm.nih.gov/pubmed/25554404
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1474-4422(14)70318-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars